134.47 0.00 (0.00%)
Pre-Market: 8:00AM EDT
|Bid||134.59 x 900|
|Ask||134.87 x 1000|
|Day's Range||132.19 - 135.00|
|52 Week Range||118.62 - 148.32|
|PE Ratio (TTM)||267.34|
|Forward Dividend & Yield||3.60 (2.68%)|
|1y Target Est||N/A|
Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business. Mr. DelOrefice holds a Bachelor of Science and MBA from Villanova University, and received his CPA certification from the Commonwealth of PA.
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Boston ...
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston ...
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017 2018 Second-Quarter EPS was $1.45 2018 Adjusted Second-Quarter EPS of $2.10 increased 14.8%* Accelerating Operational Sales Growth ...
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Johnson & Johnson (NYSE: JNJ ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 17, 2018 at 8:30 AM Eastern Time. To listen ...
NEW BRUNSWICK, N.J., July 16, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on September 11, 2018 to shareholders of record at the close of business on August 28, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...
NEW BRUNSWICK, N.J., July 12, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) issued the following statement regarding today's verdict in the St. Louis court. "Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process that allowed plaintiffs to present a group of 22 women, most of whom had no connection to Missouri, in a single case all alleging that they developed ovarian cancer.
The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning the verdict. While there have been other trials in which juries have determined that talc products contained asbestos and caused mesothelioma cancer, this case marks the first talc/asbestos-induced ovarian cancer verdict in the United States.
On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).
TITUSVILLE, N.J., June 26, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson and Johnson & Johnson Innovation LLC are joining with Mental Health America, OneMind, PeaceLove and other leading mental health and arts organizations to leverage the power of artistic creation to break down stigma about mental illnesses and build greater empathy and understanding. Champions of Science: The Art of Ending Stigma, a new global project, encourages all people to share artistic expressions about mental illnesses and the importance of overcoming stigma, while also educating about the biological basis of these diseases.
NEW BRUNSWICK, N.J. , June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the appointment of a number of senior leaders to the Company's Executive Committee. Specifically: Joaquin ...
NEW BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that Sandra (Sandi) E. Peterson, Group Worldwide Chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1, 2018. During her career at Johnson & Johnson, Ms. Peterson exercised strong portfolio discipline in the businesses she has led, clarifying priority markets and segments, and shepherding numerous deals, acquisitions and divestitures. During her tenure, the Consumer business performance showed solid improvement, the U.S. OTC business was restored to growth, and the Vision Care business regained market leadership in contact lenses and has become a leader in eye health. In the past year, the Medical Device sector has made progress strengthening its foundation to improve performance and accelerate growth. Sandi has been instrumental in developing new partnerships in the areas of data science and technology for J&J.
NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results. Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic ...
BOSTON , June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation ...
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southwestern ...
NEW BRUNSWICK, N.J., June 12, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products. The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.
NEW BRUNSWICK, New Jersey, June 13, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products. The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.
NEW BRUNSWICK, N.J., June 6, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has received a binding offer from Fortive Corporation (FTV) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive and $0.1 billion of retained net receivables. From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies (JNJ), has made significant contributions to surgery for more than 60 years.
Annual Health for Humanity Report Discloses Progress on Global Commitments and Highlights Key Achievements Toward Eradicating and Preventing Disease, Reimagining Care Delivery and Promoting Lifelong Health ...
BOSTON, June 4, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today named James Allison, Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen Award for Biomedical Research, and launched several new programs as part of our Champions of Science platform to fuel public engagement, support and trust in science. "Dr. Allison's innovative approach to treating cancer through harnessing the power of the immune system has led to breakthrough therapies that are providing hope for patients around the world," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson.